A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Antacid in Healthy Adults

← catalyst calendar

NCT06507904 · readout in 177 d

Sponsored by Pfizer (industry) · PFE — their whole pipeline →.

Phase

Phase 1

Status

Not yet recruiting

Study type

Interventional

Design

Randomized · None · Supportive care

Enrollment

52estimated

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-09-15

estimated

When the study began enrolling

Primary completion

2027-02-12

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-05-03

estimated

The whole study's end, after follow-up

First posted

2024-07-18

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-03-27

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Healthy

Interventions

Drug: Osivelotor — also filed as PF-07940367
Other: Famotidine

Primary outcomes

what the primary-completion date above is the date OF

Part 1: Mouth Feel Effect

measured 1, 5, 10, 20 minutes post dose

Part 1: Bitter effect

measured 1, 5, 10, 20 minutes post dose

Part 1: Tongue/mouth burn effect

measured 1, 5, 10, 20 minutes post dose

Part 1:Overall liking effect

measured 1, 5, 10, 20 minutes post dose

Part 2: Area under the Concentration-Time Curve (AUC 0-144) of osivelotor, as data permits

measured 0, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144 hours post-dose

Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed